Drugs / rMenB
last change Oct 2015 re-read 2 minutes ago

rMenB

Vaccine

Developed for
meningococcal infection · meningococcal meningitis
Investigated by
Novartis Vaccines

Trials 4 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01026974 Feb → Sep 2010 meningococcal infection Novartis Vaccines Completed No outcome recorded
Phase 2 NCT01027351 Jan → Sep 2010 meningococcal infection Novartis Vaccines Completed No outcome recorded
Phase 2 NCT00433914 Feb → Dec 2007 meningococcal infection Novartis Vaccines Completed No outcome recorded
Phase 2 NCT00381615 Sep 2006 → Jul 2007 Novartis Vaccines Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01367158 Comparator Jul 2011 → Jan 2012 meningococcal meningitis Novartis Vaccines Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as rMenB “BACKGROUND: In a primary study, healthy adolescents received 2 doses (months 0/2) of 1 of the 4 investigational meningococcal ABCWY vaccine formulations, containing components...” PMID 26135245 Oct 2015
4

“Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).” NCT01027351

NCT00433914

NCT01026974

NCT00381615

Modality Vaccine “rMenB vaccine without OMV-NZ” NCT00381615